BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 26774153)

  • 1. CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases.
    Napieralska A; Miszczyk L; Stapor-Fudzinska M
    Neoplasma; 2016; 63(2):304-12. PubMed ID: 26774153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CyberKnife Stereotactic Ablative Radiotherapy as an Option of Treatment for Patients With Prostate Cancer Having Oligometastatic Lymph Nodes: Single-Center Study Outcome Evaluation.
    Napieralska A; Miszczyk L; Stąpór-Fudzińska M
    Technol Cancer Res Treat; 2016 Oct; 15(5):661-73. PubMed ID: 26208835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases.
    Fanetti G; Marvaso G; Ciardo D; Rese A; Ricotti R; Rondi E; Comi S; Cattani F; Zerini D; Fodor C; de Cobelli O; Orecchia R; Jereczek-Fossa BA
    Med Oncol; 2018 Apr; 35(5):75. PubMed ID: 29671075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
    Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
    Hasan H; Deek MP; Phillips R; Hobbs RF; Malek R; Radwan N; Kiess AP; Dipasquale S; Huang J; Caldwell T; Leitzel J; Wendler D; Wang H; Thompson E; Powell J; Dudley S; Deville C; Greco SC; Song DY; DeWeese TL; Gorin MA; Rowe SP; Denmeade S; Markowski M; Antonarakis ES; Carducci MA; Eisenberger MA; Pomper MG; Pienta KJ; Paller CJ; Tran PT
    BMC Cancer; 2020 Jun; 20(1):492. PubMed ID: 32487038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).
    Habl G; Straube C; Schiller K; Duma MN; Oechsner M; Kessel KA; Eiber M; Schwaiger M; Kübler H; Gschwend JE; Combs SE
    BMC Cancer; 2017 May; 17(1):361. PubMed ID: 28532400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy.
    Hardcastle N; Hofman MS; Lee CY; Callahan J; Selbie L; Foroudi F; Shaw M; Chander S; Lim A; Chesson B; Murphy DG; Kron T; Siva S
    Radiat Oncol; 2019 Sep; 14(1):164. PubMed ID: 31488175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
    Siva S; Bressel M; Murphy DG; Shaw M; Chander S; Violet J; Tai KH; Udovicich C; Lim A; Selbie L; Hofman MS; Kron T; Moon D; Goad J; Lawrentschuk N; Foroudi F
    Eur Urol; 2018 Oct; 74(4):455-462. PubMed ID: 30227924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
    Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
    Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic Ablative Radiotherapy for Prostate Cancer-The Treatment Results of 500 Patients and Analysis of Failures.
    Miszczyk L; Namysł-Kaletka A; Napieralska A; Kraszkiewicz M; Miszczyk M; Woźniak G; Stąpór-Fudzińska M; Głowacki G; Tukiendorf A
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819870815. PubMed ID: 31462169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The results of treatment of prostate cancer bone metastases after CyberKnife radiosurgery.
    Napieralska A; Miszczyk L; Tukiendorf A; Stąpór-Fudzińska M
    Ortop Traumatol Rehabil; 2014; 16(3):339-49. PubMed ID: 25058109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY-2 clinical trial subanalysis.
    Deodato F; Pezzulla D; Cilla S; Ferro M; Romano C; Bonome P; Buwenge M; Zamagni A; Strigari L; Valentini V; Morganti AG; Macchia G
    Clin Transl Oncol; 2022 Jun; 24(6):1177-1183. PubMed ID: 34984604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer.
    Muacevic A; Kufeld M; Rist C; Wowra B; Stief C; Staehler M
    Urol Oncol; 2013 May; 31(4):455-60. PubMed ID: 21481619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer.
    Rogowski P; Trapp C; von Bestenbostel R; Schmidt-Hegemann NS; Shi R; Ilhan H; Kretschmer A; Stief C; Ganswindt U; Belka C; Li M
    Radiat Oncol; 2021 Jun; 16(1):125. PubMed ID: 34193194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases--clinical results.
    Boda-Heggemann J; Dinter D; Weiss C; Frauenfeld A; Siebenlist K; Attenberger U; Ottstadt M; Schneider F; Hofheinz RD; Wenz F; Lohr F
    Radiat Oncol; 2012 Jun; 7():92. PubMed ID: 22710033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.
    Angelov L; Mohammadi AM; Bennett EE; Abbassy M; Elson P; Chao ST; Montgomery JS; Habboub G; Vogelbaum MA; Suh JH; Murphy ES; Ahluwalia MS; Nagel SJ; Barnett GH
    J Neurosurg; 2018 Aug; 129(2):366-382. PubMed ID: 28937324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy for prostate cancer: a preliminary report.
    Lee YH; Son SH; Yoon SC; Yu M; Choi BO; Kim YS; Jang HS; Lee SN; Jang JS; Hwang TK
    Asia Pac J Clin Oncol; 2014 Jun; 10(2):e46-53. PubMed ID: 22994564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
    Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
    J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life.
    Dixit A; Tang C; Bydder S; Kedda MA; Vosikova E; Bharat C; Gill S
    J Med Radiat Sci; 2017 Sep; 64(3):180-187. PubMed ID: 28271639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.